107 related articles for article (PubMed ID: 29019022)
1. Distribution of lacosamide in the rat brain assessed by in vitro slice technique.
Gáll Z; Vancea S
Arch Pharm Res; 2018 Jan; 41(1):79-86. PubMed ID: 29019022
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, brain distribution, and plasma protein binding of the antiepileptic drug lacosamide in rats.
Koo TS; Kim SJ; Ha DJ; Baek M; Moon H
Arch Pharm Res; 2011 Dec; 34(12):2059-64. PubMed ID: 22210031
[TBL] [Abstract][Full Text] [Related]
3. Current understanding of the mechanism of action of the antiepileptic drug lacosamide.
Rogawski MA; Tofighy A; White HS; Matagne A; Wolff C
Epilepsy Res; 2015 Feb; 110():189-205. PubMed ID: 25616473
[TBL] [Abstract][Full Text] [Related]
4. Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.
Zhang YY; Liu H; Summerfield SG; Luscombe CN; Sahi J
Mol Pharm; 2016 May; 13(5):1540-50. PubMed ID: 27015243
[TBL] [Abstract][Full Text] [Related]
5. Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters.
Kodaira H; Kusuhara H; Fuse E; Ushiki J; Sugiyama Y
Drug Metab Dispos; 2014 Jun; 42(6):983-9. PubMed ID: 24644297
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of lacosamide and classical sodium channel blocking antiepileptic drugs on sodium channel slow inactivation.
Niespodziany I; Leclère N; Vandenplas C; Foerch P; Wolff C
J Neurosci Res; 2013 Mar; 91(3):436-43. PubMed ID: 23239147
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Brain Pharmacokinetic and Neuropharmacodynamic Attributes of an Antiepileptic Drug, Lacosamide, in Hepatic and Renal Impairment: Preclinical Evidence.
Kumar B; Modi M; Saikia B; Medhi B
ACS Chem Neurosci; 2017 Jul; 8(7):1589-1597. PubMed ID: 28324653
[TBL] [Abstract][Full Text] [Related]
8. Revisiting atenolol as a low passive permeability marker.
Chen X; Slättengren T; de Lange ECM; Smith DE; Hammarlund-Udenaes M
Fluids Barriers CNS; 2017 Oct; 14(1):30. PubMed ID: 29089037
[TBL] [Abstract][Full Text] [Related]
9. The brain slice method for studying drug distribution in the CNS.
Loryan I; Fridén M; Hammarlund-Udenaes M
Fluids Barriers CNS; 2013 Jan; 10(1):6. PubMed ID: 23336814
[TBL] [Abstract][Full Text] [Related]
10. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels.
Errington AC; Stöhr T; Heers C; Lees G
Mol Pharmacol; 2008 Jan; 73(1):157-69. PubMed ID: 17940193
[TBL] [Abstract][Full Text] [Related]
11. Molecular properties determining unbound intracellular and extracellular brain exposure of CNS drug candidates.
Loryan I; Sinha V; Mackie C; Van Peer A; Drinkenburg WH; Vermeulen A; Heald D; Hammarlund-Udenaes M; Wassvik CM
Mol Pharm; 2015 Feb; 12(2):520-32. PubMed ID: 25496026
[TBL] [Abstract][Full Text] [Related]
12. Translational CNS Steady-State Drug Disposition Model in Rats, Monkeys, and Humans for Quantitative Prediction of Brain-to-Plasma and Cerebrospinal Fluid-to-Plasma Unbound Concentration Ratios.
Sato S; Matsumiya K; Tohyama K; Kosugi Y
AAPS J; 2021 Jun; 23(4):81. PubMed ID: 34085128
[TBL] [Abstract][Full Text] [Related]
13. Innovative in vitro method to predict rate and extent of drug delivery to the brain across the blood-brain barrier.
Mangas-Sanjuan V; González-Álvarez I; González-Álvarez M; Casabó VG; Bermejo M
Mol Pharm; 2013 Oct; 10(10):3822-31. PubMed ID: 23977999
[TBL] [Abstract][Full Text] [Related]
14. In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids.
Fridén M; Gupta A; Antonsson M; Bredberg U; Hammarlund-Udenaes M
Drug Metab Dispos; 2007 Sep; 35(9):1711-9. PubMed ID: 17591680
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetic and pharmacodynamic profile of lacosamide.
Cawello W
Clin Pharmacokinet; 2015 Sep; 54(9):901-14. PubMed ID: 25957198
[TBL] [Abstract][Full Text] [Related]
16. Development of a sensitive bioanalytical method for the quantification of lacosamide in rat plasma. Application to preclinical pharmacokinetics studies in rats.
Shah S; Vasantharaju SG; Arumugam K; Muddukrishna BS; Desai N
Arzneimittelforschung; 2012 May; 62(5):243-6. PubMed ID: 22382788
[TBL] [Abstract][Full Text] [Related]
17. Liquid chromatography-tandem mass spectrometry for quantification of lacosamide, an antiepileptic drug, in rat plasma and its application to pharmacokinetic study.
Kim SJ; Koo TS; Ha DJ; Baek M; Lee SK; Shin DS; Moon H
Biomed Chromatogr; 2012 Mar; 26(3):371-6. PubMed ID: 21735462
[TBL] [Abstract][Full Text] [Related]
18. Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
Fridén M; Bergström F; Wan H; Rehngren M; Ahlin G; Hammarlund-Udenaes M; Bredberg U
Drug Metab Dispos; 2011 Mar; 39(3):353-62. PubMed ID: 21149540
[TBL] [Abstract][Full Text] [Related]
19. Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats.
Brandt C; Heile A; Potschka H; Stoehr T; Löscher W
Epilepsia; 2006 Nov; 47(11):1803-9. PubMed ID: 17116018
[TBL] [Abstract][Full Text] [Related]
20. Chimeric agents derived from the functionalized amino acid, lacosamide, and the α-aminoamide, safinamide: evaluation of their inhibitory actions on voltage-gated sodium channels, and antiseizure and antinociception activities and comparison with lacosamide and safinamide.
Park KD; Yang XF; Dustrude ET; Wang Y; Ripsch MS; White FA; Khanna R; Kohn H
ACS Chem Neurosci; 2015 Feb; 6(2):316-30. PubMed ID: 25418676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
